CardioSource WorldNews | Page 7
LIVE
COURSES
2016
May 5–7
Recent Advances in Clinical
Nuclear Cardiology and
Cardiac CT: State of the Art
Updates & 101 EvidenceBased Case Reviews
October 20–22
Heart Valve Summit: Medical,
Surgical & Interventional
Decision-Making Course
Radisson Blu Aqua Hotel
Chicago, IL
October 8
October 15
Lexington Convention Center
Lexington , KY
Columbus Hotel at Easton
Columbus, OH
Kentucky Chapter Annual
Meeting 2016
B:7.875 in
Ohio Chapter Annual Meeting
2016
T:7.5 in
Capital Hilton
Washington, DC
S:7 in
June 4–7
Add Corlanor ® to maximally tolerated doses of beta-blockers and help give
World Heart Federation |
World Congress of Cardiology
& Cardiovascular Health 2016
appropriate patients with heart rate ≥ 70 bpm and stable, symptomatic chronic HF...
MORE HOME. LESS HOSPITAL.
Mexico City, Mexico
June 3–4
Bringing Science to Clinical
Practice: Best of ACC.16
1 Hotel South Beach
Miami, FL
June 17–18
Care of the Athletic Heart:
Translating Clinical Science
into Practice Strategies
The Westin Houston-Memorial City
Houston, TX
August 19–21
Florida Chapter Annual
Meeting 2016
Disney’s Yacht Club Resort
Orlando, FL
August 26–28
Learn how you can DO MORE with Corlanor® to reduce the risk
of hospitalization for worsening heart failure (HF)
ACC/SCAI Premier
Interventional Cardiology
Overview & Board
Preparatory Course
The Ritz-Carlton
Amelia Island, FL
September 6–10
The ACC Cardiovascular Board
Review for Certification &
Recertification
The Swissotel
Chicago, IL
September 14– 17
Core Curriculum for the
Cardiovascular Clinician
Heart House
Washington, DC
September 23–25
NC/SC Chapters Annual
Meeting 2016
Kiawah Island Golf Resort
Kiawah Island, SC
1
CorlanorHCP.com
Indication
Corlanor® (ivabradine) is indicated to reduce the risk of hospitalization
for worsening heart failure in patients with stable, symptomatic
chronic heart failure with left ventricular ejection fraction ≤ 35%, who
are in sinus rhythm with resting heart rate ≥ 70 beats per minute and
either are on maximally tolerated doses of beta-blockers or have a
contraindication to beta-blocker use.
Important Safety Information
Contraindications: Corlanor® is contraindicated in patients with
acute decompensated heart failure, blood pressure < 90/50 mmHg,
sick sinus syndrome, sinoatrial block, 3rd degree atrioventricular
block (unless a functioning demand pacemaker is present), a resting
heart rate < 60 bpm prior to treatment, severe hepatic impairment,
pacemaker dependence (heart rate maintained exclusively by the
pacemaker), and concomitant use of strong cytochrome P450 3A4
(CYP3A4) inhibitors.
Fetal Toxicity: Corlanor® may cause fetal toxicity when administered
to a pregnant woman based on embryo-fetal toxicity and cardiac
teratogenic effects observed in animal studies. Advise females to use
effective contraception when taking Corlanor®.
Atrial Fibrillation: Corlanor® increases the risk of atrial fibrillation.
The rate of atrial fibrillation in patients treated with Corlanor®
compared to placebo was 5% vs. 3.9% per patient-year, respectively.
Regularly monitor cardiac rhythm. Discontinue Corlanor® if atrial
fibrillation develops.
© 2015 Amgen Inc. All rights reserved. Not for reproduction. USA-998-115485 11-15
Bradycardia and Conduction Disturbances: Bradycardia, sinus
arrest and heart block h fR